Boehringer’s big cancer reveal draws near

Boehringer Ingelheim has been trying to become a big gun in cancer for years. So far, it has fallen short of its ambition, but it hopes that things might begin to change in 2021.

A big focus for Boehringer is its Kras portfolio, with the company’s global head of innovation, Michel Pairet, telling Evaluate Vantage that its strategy here will be unveiled at the upcoming AACR meeting. But Boehringer is also investing in antibody-drug conjugates, via its recent acquisition of NBE-Therapeutics, T-cell engagers and cancer vaccines.